Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTX – Research Report) and ...

Join us for a quick overview of BioNTech SE, a Biotechnology company whose shares moved 0.3% today. Here are some facts about ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on BioNTech SE (BNTX – Research Report). The ...

In its decision, the Opposition Division largely dismissed the opposition originally filed by BioNTech SE in April 2023 challenging the patent's validity and maintained the patent in amended form. The ...

In its decision, the Opposition Division largely dismissed the opposition originally filed by BioNTech SE in April 2023 challenging the patent's validity and maintained the patent in amended form.

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and collaborators Pfizer+BioNTech seeking damages based on their respective sales ...

This stipulation also does not address the litigation GSK initiated in 2024 against Pfizer, Pharmacia & Upjohn, BioNtech SE, BioNtech Manufacturing GmbH, and BioNTech US, Inc. In that case ...

The NCAA informed him Tuesday that the correct and current WMU logo would be in place in time for Thursday's national semifinals. It actually was fixed as of Tuesday night. "Yesterday, we noted an ...

Below is Validea's guru fundamental report for BIONTECH SE - ADR (BNTX). Of the 22 guru strategies we follow, BNTX rates highest using our Value Investor model based on the published strategy of ...